Generics market share in Europe

Home/Reports | Posted 22/01/2016 post-comment0 Post your comment

Generics make a major contribution to the European drug supply, according to a report by the by Germany-based Institute for Healthcare and Social Research (IGES).

28 MD002360

In most European countries, the market share of generic medicines by volume is more than 40%, see Figure 1. Germany, which is the biggest pharmaceutical market in Europe, had the highest volume share of generics of 73% in 2014. While the UK, which falls in fourth place in Europe, the generics volume share in 2014 was 66%. However, the volume shares differ noticeably among the European countries, with Greece having the lowest generics volume share of 27%.

Figure1: European generics market share 2014


The differences between European countries are attributed by IGES to their different institutional settings and different policies to promote generics substitution or international non-proprietary name (INN) prescribing [1].

The share of generics by value is in most European countries distinctly lower than in volume. The exception to this is Greece, where the generics share by value is 19% and by volume 27%, a difference of only 8%. The largest differences between the generics share by volume and by value were found in Denmark (46%) and Sweden (42%).

Related articles

Impact of antidepressant generics in Europe

Impact of breast cancer generics in Europe

Impact of hypertension generics in Europe

Impact of generics on European budgets

Generics reduce costs and increase access

1.  Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries─an overview. Generics and Biosimilars Initiative Journal (GaBI Journal). 2012;1(2):93-100. doi:10.5639/gabij.2012.0102.020 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010